DAFTAR PUSTAKA 1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. 2010;127:2893-917. 2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman,D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. 3. Aziz, M.,F. Gynecological cancer in Indonesia. J Gynecol Oncol. 2009;20(1-8):8-10. 4. Nguyen L, Brewer CA, DiSaia PJ. Ovarian metastasis of stage IIB squamous cell cancer of the cervix after radical parametrectomy and oophoropexy. Gynecologic Oncology. 1998; 68:198 200. 5. Kurnia I, Et Al. Hubungan Antara Biomarker Proliferasi Sebelum dan Setelah Radiasi 10 Gy dengan Respon Kemoradioterapi Kanker Serviks. Seminar Nasional Keselamatan Kesehatan dan Lingkungan VI. Jakarta, 15-16 Juni 2010. 6. Sharma R, Firdaus H, Maheshwari V, et al. Chemotherapy and Management of Locally Advanced Carcinoma Cervix. Iranian Journal of Pathology. 2012. 7 (4), 224 30 7. Kim J Y, Cho H Y, Lee KC, Hwang YJ, Lee M H et al. Tumor Apoptosis In Cervical Cancer: Its Role As A Prognostic Factor In 42 Radiotherapy Patients. Int. J. Cancer ( Radiat. Oncol. Invest) :96, 305-312.2001 8. Hausen, H.Z., Papilloma Viruses and Cancer : From Basic Studies To Clinical Application. Nature Publish Group. 2002. P.342-349. 73
9. Hietanen S, Lain S, Krausz E, Blattner C, Lane D P,. activation of p53 in cervical carcinoma cells by small molecules. Proc. Natl. Acad. Sci, U.S.A. 97: 8501-8505. 2000. 10. Wong. R.S.Y. Apoptosis in Cancer : From Pathogenesis to Treatment. Journal Of Experimental & Clinical Cancer Research.2011. p. 1-14 11. Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The Effect Of P53 Status And Human Papillomavirus Infection On The Clinical Outcome Of Patients With Stage IIIB Cervical Carcinoma Treated With Radiation Therapy Alone. Wiley Online Library. Volume 91. Issue 1. 2001. P 80-89 12. Syaifudin, M. 2007. Gen Penekan Tumor p53, Kanker dan Radiasi Pengion (serial online), [cited 29 th April 2016]. Available from: URL: http://www.batan.go.id/ptkmr/biomedika/publikasi%202007/ms_balar a_vol_8_3_apr07.pdf. 13. Kurnia I, Siregar B, Soetopo S, Ramli I, Kurjana T,et al. Correlation Between Akt and p53 Expression and Chemoradiotheraphy Response in Cervical Cancer Patients. Hayati Journal of Biosciences, Des 2014, vol. 21, no.4, p. 173-179. 14. Hanprasertpong J, Tungsinmunkog K, Chichareon S, Wootipoom V, Geater A, Et Al. Correlation Of p53 And Ki-67 (MIB- 1) Expression With Clinicopathological Features and Prognosis of Early Stage Cervical Squamous Cell Carcinoma, J. Obstet. Gynaecol. Res. Vol 36, no. 3, p. 572-580, june 2010. 15. Bai, L. & Zhu, G. 2006. p53: Structure, Function and Therapeutic 74
Applications. (serial online), [cited 29 th April 2016]. Available from : URL: http://mupnet.com/ JOCM%202(4)%20141-153.pdf. 16. Kumar, V., Kabbas, A., Fausto, N. 2010. Robbins and Cotran Pathologic Basis of Disease 8th ed. (serial online), [cited 29 th April 2016]. Available from: URL: http://www.microsoft.com/isapi/redir.dll?prd=ie&pver=6&ar=msnhome. 17. Ocviyanti D, Handoko Y. Peran Dokter Umum dalam Pencegahan Kanker Serviks di Indonesia. J Indon Med Assoc, Januari 2013, Vol: 63(1). 18. Sukardja, I Dewa Gede., 2000. Onkologi Klinik. Surabaya : Airlangga University Press. 19. Mardjikoen, prastowo., 2005. Tumor Ganas Alat Genitalia. Edisi kedua. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo 20. Pecorelli S. FIGO Committee On Gynecologic Oncology. Revised FIGO Staging for Carcinoma of The Vulva, Cervix, and Endometrium. International Journal of Gynecology and Obstetrics 105 (2009) 103-104 21. Farid A, Gynecological cancer in Indonesia. J. Gynecol oncol.2009. Maret:20(1):8-10. 22. Tjokronagoro, M. Biologi Sel Tumor Maligna. Fakultas Kedokteran UGM, 2001. 23. American Cancer Society. The Science Behind radiation Therapy. Available at URL : www.cancer.org/acs/groups/cid/documents/webcontent/003019-pdf.pdf 75
24. Dubben H.H, Thames H.D, Beck H, Tumor volume : a basic and specific response predictor in radiotherapy, Radiotherapy and Oncology, 47 (1998), p: 167-174. 25. Okaichi K, Izumi N, Takamura Y, Fukui S, Kudo T. Radiation Sensitivity And Transcription Profiles In Various Mutant P53 Cells. Department of radioisotope medicine, atomic bomb disease and hibakusha medicine unit. Available at URL : cdn.intechopen.com/pdfs/32090.pdf 26. Bhardwaj S. Wani F A. Evaluating The Importance Of Apoptotic Index, Mitotic Index And Turnover Index In Premalignant And Malignant Lesion Of Cervix. Open Journal of Pathology, 2015, 5, 29-37. 27. Gupta K. Alam K, Maheshwari V, Khan R, Sharma R. Apoptotic index and Mib-1 Antibody Expression In Premalignant And Malignant Lesion Of Uterine Cervix. Gynecol Obstet. 2013,3:5 28. Hockel M. Sclenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer research 59, 4525-4528. 1999 29. Ambari E et al. Kaspase-3 tidak dapat Digunakan sebagai Prediktor Keberhasilan Pemberian Kemoterapi Neoajuvan Regimen PVB pada Kanker Serviks Stadium IB-IIA. Indones J Obstet Gynecol Vol 37, No 3, July 2013. 30. Wiebe E, Denny L, Thomas G. Cancer of the Cervix Uteri. FIGO Cancer Reort 2012. International Journal of Gynecology & Obstetrics 119S2 (2012) S100 S109. 76
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumor. J Natl Cancer Inst 2000; 92: 205 16. 32. Park OJ. 2003. Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. Jpn J Clin Oncol 2003;33(10)533 537 33. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologist. The British Journal of Radiology, 74(2001), 983 986 34. Cervical Cancer. Dalam Berek and Haecker, Gynecologic Oncology, 5 th edition. Lippincott Williams Publisher, 2010. 35. Maae E, Nielsen M, Steffensen KD, Jakobsen EH, Jakobsen A, Sorensen FB. Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. J Histochemist cytochemist. 2011;59:750-60. 36. National Cancer Institute. NCI dictionary of cancer terms. DIakses tanggal 11 Januari 2017. Terdapat di: http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=653117 37. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, Sunamori M, et al. Sex steroid hormone receptors in human thymoma. J Clinic Endocrinol Metabolism. 2003;88(5):2309-17. 38. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz APN, Metzger GJ, Schmechel SC. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagnos Pathol. 2012;7:1-10. 77
39. Qureshi A, Pervez S. Allred scoring for ER reporting and it s impact in clearly distinguishing ER negative from ER positive breast cancers. J Pak Med Assoc. 2010;60:350-3. 40. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochemist Cytochemist. 2010;58:95-107. 41. Harvey JM, Remmele W, Goldhirsch A, Wolff AX. IVD certified breast cancer panel. Immunohistology Breast Pathology. 2013. p1-2. Available from : http://www.zytomed-systems.com/downloads/productflyer/immunohistology/262-ivd-certified-breast-cancer-panel/file.html. [Accessed 11 st January 2017] 42. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, Prasad V, Hommann M. Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012;5(3):187-94. 43. Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue a review. Fedchenko and Reifenrath Diagnostic Pathology. 2014;9:1-12. 44. Gasinska A, Urbanski K, Gruchala A, Biesaga B, Kojs Z. A Ratio Of Apoptosis To Mitosis, Proliferation Pattern And Prediction Of Radiotherapy Response In Cervical Carcinoma. Laboratory of Radiation Biology. Neoplasma. 49.6. 2002 78
45. Jain D, Srinivasan R, Patel F, Gupta S. Evaluation of p53 and Bcl-2 Expression Asprognostic Markers In Invasive Cervical Carcinoma Stage IIB/III Patients Treated By Radiotherapy. Gynecologic Oncology 88, 22-28. 2003 46. Singh A, Sharma H, Salhan S, Guppta S, Bhatla N et al. Evaluation Of Expression Of Apoptosis-Related Proteins And Their Correlation With HPV, Telomerase Activity, Apoptoticindex In Cervical Cancer. Pathobiology. 2004;71:314-322. 47. Horn L, Fischer U, Hanel C, Kuhn H, Raptis G, Bilek B. p53 in Surgically Treated And Pathologically Staged Cervical Cancer: Correlation With Local Tumor Progression, But Not With Lymphatic Spread. Pathol. Res. Pract. 197: 605-609 2011. 48. Carrilho C, Gouveia P, Cantel M, Matos A, Buane L, David L. Characterization Of Human Papillomavirus Infection, p53 and Ki-67 Expression In Cervical Cancer Of Mozambican Women. Pathol. Res. Pract. 199: 303-311. 2003 49. Vosmik M, Laco J, Sirak I, Beranek M, Hovorkova E et al. Prognostic Significance Of Human Papillomavirus (HPV) Status And Expression Of Selected Markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome After (Chemo-) Radiotherapy In Patients With Squamous Cell Carcinoma Of Uterine Cervix. Springer. Path. Oncol. Res.2013 79